199 related articles for article (PubMed ID: 3508715)
21. Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation.
van der Pluijm G; Mouthaan H; Baas C; de Groot H; Papapoulos S; Löwik C
J Bone Miner Res; 1994 Jul; 9(7):1021-8. PubMed ID: 7942148
[TBL] [Abstract][Full Text] [Related]
22. [Inhibitory effects of bisphosphonates on bone resorption].
Shinoda H
Nihon Yakurigaku Zasshi; 1995 May; 105(5):285-94. PubMed ID: 7628780
[TBL] [Abstract][Full Text] [Related]
23. Low doses of uranium and osteoclastic bone resorption: key reciprocal effects evidenced using new in vitro biomimetic models of bone matrix.
Gritsaenko T; Pierrefite-Carle V; Creff G; Simoneau B; Hagège A; Farlay D; Pagnotta S; Orange F; Jaurand X; Auwer CD; Carle GF; Santucci-Darmanin S
Arch Toxicol; 2021 Mar; 95(3):1023-1037. PubMed ID: 33426622
[TBL] [Abstract][Full Text] [Related]
24. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
25. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
26. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
28. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.
Murakami H; Takahashi N; Sasaki T; Udagawa N; Tanaka S; Nakamura I; Zhang D; Barbier A; Suda T
Bone; 1995 Aug; 17(2):137-44. PubMed ID: 8554921
[TBL] [Abstract][Full Text] [Related]
29. Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall MJ; Holt I; Davie MW
Calcif Tissue Int; 1993 Jan; 52(1):21-5. PubMed ID: 8453501
[TBL] [Abstract][Full Text] [Related]
30. Linarin and its aglycone acacetin abrogate actin ring formation and focal contact to bone matrix of bone-resorbing osteoclasts through inhibition of αvβ3 integrin and core-linked CD44.
Kim SI; Kim YH; Kang BG; Kang MK; Lee EJ; Kim DY; Oh H; Oh SY; Na W; Lim SS; Kang YH
Phytomedicine; 2020 Dec; 79():153351. PubMed ID: 32987362
[TBL] [Abstract][Full Text] [Related]
31. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
Selander K; Lehenkari P; Väänänen HK
Calcif Tissue Int; 1994 Nov; 55(5):368-75. PubMed ID: 7532540
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
34. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.
Reitsma PH; Bijvoet OL; Verlinden-Ooms H; van der Wee-Pals LJ
Calcif Tissue Int; 1980; 32(2):145-57. PubMed ID: 6773632
[TBL] [Abstract][Full Text] [Related]
35. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation.
Valcourt U; Merle B; Gineyts E; Viguet-Carrin S; Delmas PD; Garnero P
J Biol Chem; 2007 Feb; 282(8):5691-703. PubMed ID: 17142454
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Vitté C; Fleisch H; Guenther HL
Endocrinology; 1996 Jun; 137(6):2324-33. PubMed ID: 8641182
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
38. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones.
Tobias J; Chambers TJ
Endocrinology; 1989 Sep; 125(3):1290-5. PubMed ID: 2759026
[TBL] [Abstract][Full Text] [Related]
39. The cellular mechanism of action of bisphosphonates.
Hughes DE; Mian M; Guilland-Cumming DF; Russell RG
Drugs Exp Clin Res; 1991; 17(2):109-14. PubMed ID: 1864224
[TBL] [Abstract][Full Text] [Related]
40. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
